CD276 and colorectal cancer: Given the current limitations of anti-immune checkpoint therapy in colorectal cancer, which is only applicable to 10–15% of patients with high microsatellite instability (MSI-H) [38], B7-H3 CAR-T cells have the potential to benefit a larger number of patients with incurable distant metastasis, if their efficacy is further confirmed by clinical trials.